Clinical Trials At Southeast Nebraska Cancer Center


WO39210 – A Phase III, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Atezolizumab (anti-PD-L1 antibody) as adjuvant therapy in patients with renal cell carcinoma at high risk of developing metastasis following nephrectomy.

KEYNOTE 679 – A Randomized, Open-Label, Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475/Keytruda) plus Epacadostat vs Standard of Care (Sutent or Votrient) as First Line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC)


CONNECT MDS/AML – The Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

MAGNIFY – Phase III Randomized study of lenalidomide (CC-5013) plus rituximab maintenance therapy followed by lenalidomide single-agent maintenance versus rituximab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma.

informCLL- A Disease Registry for Patients with Chronic Lymphocytic Leukemia

PERSPECTIVE – A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naive Subjects with Follicular Lymphoma

UNITY 205 – A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 (Umbralisib) with or without Bendamustine and TGR-1202 (Umbralisib) alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma